Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4011-4020 Newer>

Pharmaceutical Executive July 30, 2007 Jill Wechsler	Washington Report: Exclusivity vs. Patents To encourage innovation while supporting access to less costly therapies, Congress proposes an extensive data-exclusivity period that would delay Food and Drug Administration approval of a follow-on biologic application for 12 years.
Pharmaceutical Executive July 30, 2007 Patrick Clinton	From the Editor: The Price is Wrong A judge found a few pharma companies innocent and a few guilty. But in her written opinion, everybody - regulators, payers, and pharma alike - shares the blame for inflated AWPs, and no one looks innocent.
Pharmaceutical Executive July 30, 2007 Stewart Young	Marketing to Professionals: The Essence of a Brand Beyond good messaging, marketers must establish a brand that is forever etched into physicians' minds.
Pharmaceutical Executive July 30, 2007 George Koroneos	Meetings: Pump Up the Meeting New tactics and technologies jazz up the old-fashioned pharmaceutical meeting or convention.
Pharmaceutical Executive July 30, 2007	Direct to Consumer: Creativity Through Understanding Creative consumer campaigns begin with a clear understanding of pharma rules and regulations.
Pharmaceutical Executive July 30, 2007 Peter Pitts	Opinion: Fewer Cents, More Sense Our healthcare system may be broken, but playing the blame game is not going to fix it. Remember that disease - not Big Pharma - is the enemy.
Pharmaceutical Executive July 30, 2007 Sarah Houlton	Global Report: Make Resistance Futile Patients are losing the battle against bacteria. Can pharma be convinced to swing the sword of new antibiotic development?
The Motley Fool August 9, 2007 Brian Lawler	BioMarin Gets Busy BioMarin Pharmaceutical has a busy remainder of 2007 ahead of it, including regulatory decisions, six clinical trials, and the potential for new products to enter the pipeline.
The Motley Fool August 9, 2007 Brian Lawler	Depomed Is Distressed Depomed announces its distressing second-quarter financial results, with failed phase 3 studies and under-performing drugs.
The Motley Fool August 9, 2007 Billy Fisher	ResMed Rests Easy Pillowed by healthy sales, medical-device maker ResMed dreams of future expansion, after reporting a healthy fourth-quarter.
<Older 4011-4020 Newer> Return to current articles.